Zentalis Pharmaceuticals awarded 136,000 non-qualified stock options to four newly hired employees as an inducement to join the company, under Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $1.85, matching the stock's closing price on the grant date, a 10-year term, and vest over four years contingent on continued employment. This move supports Zentalis' growth as it advances its investigational ovarian cancer treatment, azenosertib. The inducement plan aims to attract talent critical for the company's late-stage clinical development efforts.
Zentalis Pharmaceuticals' stock options have an exercise price of $1.85, matching the closing price on the grant date. For readers following the health sector, here is Pluang's market snapshot as of Nov 03, 2026 04:41 WIB: out of 150 priced US health stocks, 49 rose and 99 fell. Notable movers include TXG at USD 61.78 with a 1-day change of -11.88% and typical hold time of 92 days, SLS at USD 8.57 down 11.38% with a typical hold time of 9 days, and DFTX at USD 32.40 down 10.82% with a typical hold time of 14 days.
Dianthus Therapeutics, a clinical-stage biotech company, granted stock options to three new non-executive employees as inducements for joining the company. The options cover 26,000 shares at an exercise price of $82.25, vesting over four years. This ...
The Federal Home Loan Bank of Atlanta announced the election of three new member directors and the re-election of one independent director to its board for 2026. Suzanne DeFerie was named Chair and Kathy McKinney Vice Chair for 2027, ensuring experie...
Amazon.com is reinforcing its market position with AWS backlog surging to $580 billion and aiming for a $1 trillion revenue run rate. Despite concerns over aggressive AI-related capital expenditures and delayed free cash flow recovery, management jus...
Exosens has released its monthly update on the total number of shares and voting rights composing its capital as of October 31, 2026. The company reports 50,936,749 total shares and 59,425,768 theoretical voting rights, with 59,162,039 exercisable vo...
Exosens disclosed its monthly update on the total number of shares and voting rights in its share capital as of October 31, 2026. The company has 50,936,749 shares outstanding, with 59,162,039 exercisable voting rights after deducting treasury shares...
